Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TLSCHECK

Financiado

Cerrado

Regulation of pol eta by phosphorylation ubiquitination and SUMOylation

Xeroderma pigmentosum variant (XPV) is an autosomal recessive genetic disorder that results in enhancced predisposition to skin cancers. XPV results from a defect in the translesion synthesis (TLS) polymerase poleta. TLS allows by... ver más

29/02/2016

CNR

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-02-29 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CNR

0.00€ | Lider

Proyectos interesantes

DAMAGE BYPASS

Medical Technol...

Applied Physics

2M€ Cerrado

DDREGULATION

Medical Technol...

Applied Physics

2M€ Cerrado

BFU2015-69709-P

Medical Technol...

Applied Physics

142K€ Cerrado

EPINER2007

Medical Technol...

Applied Physics

15K€ Cerrado

PID2019-104423GB-I00

Medical Technol...

Applied Physics

157K€ Cerrado

ERC-ID

Medical Technol...

Applied Physics

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Xeroderma pigmentosum variant (XPV) is an autosomal recessive genetic disorder that results in enhancced predisposition to skin cancers. XPV results from a defect in the translesion synthesis (TLS) polymerase poleta. TLS allows bypass of unrepaired damage permitting completion of replication. Poleta is phosphorylated and ubiquitinated and can interact with ubiquitin and SUMO, two post-translational modifications that are important in a number of DNA repair pathways, via multiple domains. Mutants in those domains show a defect in DNA damage checkpoint activation, pointing out an unexpected connection between TLS and one of the DNA damage surveillance mechanisms. TLS is regulated by ubiquitination of the proliferating cell nuclear antigen (PCNA). While PCNA ubiquitination is essential for TLS, new evidence suggests that is not needed for the initial recruitment of the polymerases to chromatin. The objective of this proposal is to identify how poleta’s function is modulated by interaction of a number of unknown factors with its different domains, ensuring both its recruitment when needed and its inhibition when its action would be deleterious for normal replication. I propose to dissect the checkpoint activation cascade to unveil the role of poleta in this pathway, analyze known factors involved in both the ubiquitination and SUMOylation pathways and to conduct a proteomic study of poleta to identify novel interactors which will be assayed for TLS functionality in vivo. Insight into the function of a core cancer protection pathway, plus the potential identification of new and important partners controlling poleta will lead to finding new diagnostically relevant biomarkers for XPV patients in whom mutations in poleta have not been found. In the long-term, Y-family polymerases are likely candidate targets for synthetic lethality strategies in cancer treatment and thus a mechanistic understanding of their function will be essential to designing rational therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores